What animal models does Creative Biolabs use for atherosclerosis targeting?

We routinely work with ApoE knockout (ApoE-/-) and LDL receptor knockout (LDLR-/-) mice fed on a high-fat diet to develop robust atherosclerotic plaques.

Can Creative Biolabs screen for ligands that differentiate early versus advanced plaques?

Yes, by adjusting circulation time, tissue collection points, and validation assays, we can help you discover ligands specific to plaque maturity stages.

How are peptides validated after in vivo screening?

Typically, we perform ex vivo binding assays, histological co-localization studies, and optionally in vivo imaging studies to validate specificity.

How long does an atherosclerosis-targeting project take?

Standard timelines range from 10–16 weeks, depending on project complexity and validation requirements.

Can I request multiple tissue targets within the same screening campaign?

Absolutely. Creative Biolabs can design multiplex targeting projects upon request to maximize the output of a single screening run.

Atherosclerosis Targeting In Vivo Phage Library Screening Service

Introduction Our Services Workflow Platform Advantages Deliverables FAQ Resources

Introduction

Atherosclerosis remains a major cause of cardiovascular disease and stroke in the community at large. Therapeutics and imaging agent targeted delivery to atherosclerotic plaques is expected to revolutionize diagnosis, treatment, and patient-centered care for atherosclerosis. Specializing in Atherosclerosis Targeting In Vivo Phage Library Screening Services, Creative Biolabs provides custom services in the field of targeting atherosclerosis with phage.

We at Creative Biolabs appreciate the molecular biology of vascular diseases and the desire for specific, well-defined instruments to shortly differentiate between diseased and healthy vascular tissues. Using our advanced in vivo phage display technology, we provide researchers with unparalleled access to customized ligand discovery solutions that reflect true physiological conditions.

Our Services

Creative Biolabs offers a comprehensive package of services for atherosclerosis-targeted peptide discovery through in vivo phage library screening. Our expertise covers every stage of the process, including but not limited to:

Construction or utilization of high-diversity phage libraries (10⁹ unique clones or greater).

Large and diverse phage libraries provide a comprehensive pool of peptide or antibody variants, increasing the probability of identifying high-affinity binders. Each clone represents a unique sequence that can interact with distinct structural or chemical features of the atherosclerotic plaque.

Animal model establishment (e.g., ApoE-/- mice or LDLR-/- mice) featuring reliable atherosclerosis development.

Robust in vivo models are critical for mimicking human atherosclerotic plaque formation and progression. Using genetically modified mice ensures consistent lesion development for accurate screening of phage-displayed libraries.

Systemic administration of phage libraries to allow circulation and plaque targeting.

Phage particles are injected into the bloodstream, enabling natural biodistribution and binding to disease-relevant tissues. This process allows in vivo selection of peptides capable of homing to atherosclerotic plaques under physiological conditions.

Precise tissue harvesting from the aorta and arteries rich in plaques, ensuring specific recovery.

After circulation, organs and vessels containing plaques are carefully dissected to recover bound phages. This precise isolation ensures enrichment of clones that specifically interact with plaque-associated molecular targets.

Stringent washing and enrichment to minimize non-specific binding.

Multiple washing steps under optimized conditions remove weakly or nonspecifically bound phages. This enhances the selection fidelity and enriches only the strongest, biologically relevant interactions.

Multiple rounds of biopanning to progressively enrich for high-affinity atherosclerotic plaque binders.

Iterative rounds of selection and amplification refine the pool toward highly specific and high-affinity clones. Each round increases the representation of potent plaque-targeting sequences while eliminating background noise.

Sequence analysis and candidate identification using Sanger sequencing or next-generation sequencing (NGS).

Sequencing of enriched clones reveals consensus motifs or novel binding sequences associated with plaque recognition. Advanced bioinformatics tools are then used to identify and prioritize top candidates for validation.

Validation assays include ex vivo binding, immunofluorescence imaging, and plaque targeting assessment.

Identified candidates are further verified in follow-up assays to confirm their plaque-binding ability. These experiments demonstrate biological relevance and visualize the targeting efficiency within vascular tissues.

Workflow

Creative Biolabs' atherosclerosis targeting workflow is built on years of refinement and optimization. Our standard process typically includes:

Library Preparation

Use of a pre-existing peptide phage library or custom construction based on project needs.

Animal Injection

Intravenous injection of the library into atherosclerotic animal models under controlled conditions.

Circulation Time

Allow sufficient circulation for phages to interact naturally with vascular plaques.

Tissue Harvesting

Extraction of target tissues (e.g., carotid arteries) containing atherosclerotic plaques.

Phage Recovery and Amplification

Isolation and expansion of plaque-binding phages.

Sequential Biopanning Rounds

Three to five rounds of enrichment to achieve high specificity.

Candidate Analysis

Sequencing and bioinformatics analysis to determine peptide sequences.

Peptide Validation

In vitro and ex vivo validation using immunohistology, plaque-binding assays, and imaging.

Every step is executed by Creative Biolabs' expert scientific team with strict quality control to ensure reproducibility and reliability.

In Vivo Screening Platform

Creative Biolabs' in vivo phage display platform offers a highly effective route to ligand discovery that respects the full biological context of living systems. Unlike conventional in vitro methods, our platform integrates key physiological barriers—vascular delivery, immune system filtration, and extracellular matrix complexity—ensuring the identification of ligands that are viable in real-world settings.

Highlights of Creative Biolabs' platform include:

High-Diversity Libraries: Screening campaigns with libraries exceeding 10⁹ different clones.
True Physiological Relevance: Natural selection pressures in live animals guarantee functional ligand candidates.
Selective Tissue Targeting: Ability to distinguish between diseased versus healthy vascular areas.
Flexible Screening Design: Adaptable to different animal models, targets, and project goals.

Additionally, Creative Biolabs offers other optional phage display screening programs to meet diverse research needs, including:

Fig.1 Muscle Targeting. (Creative Biolabs AI)

In Vivo Phage Display for Muscle Targeting

Fig.2 Synovium Targeting. (Creative Biolabs AI)

In Vivo Phage Display for Human Synovium Targeting

Fig.3 Tumor Targeting. (Creative Biolabs AI)

In Vivo Phage Display for Tumor Targeting

Fig.4 Endothelium Targeting. (Creative Biolabs AI)

In Vivo Phage Display for Vascular Endothelium Targeting

Our platform provides unmatched versatility and rigor, ensuring your project receives the highest-quality output. Find out how to get involved here.

Advantages

By partnering with Creative Biolabs for your atherosclerosis targeting project, you gain access to:

Deep Scientific Expertise

Our team brings years of hands-on experience in both cardiovascular disease modeling and phage display screening. We have worked extensively with diverse in vivo and in vitro atherosclerosis models, allowing us to design highly relevant experiments that reflect real disease conditions. This deep understanding enables us to interpret results with scientific precision and guide clients toward meaningful translational outcomes.

High Specificity and Affinity

Through optimized biopanning strategies and stringent selection protocols, we ensure the identification of ligands with superior specificity and affinity. These ligands can reliably differentiate atherosclerotic plaques from healthy vascular tissues, providing strong foundations for diagnostic, imaging, or targeted therapeutic applications.

Customized Solutions

We understand that every cardiovascular study is unique. Our scientists tailor each project based on your specific needs - whether it involves plaque stage (early or advanced), target molecule type (protein, peptide, or cell-surface marker), or animal model species. This flexibility ensures that every discovery is biologically relevant and directly aligned with your research goals.

Seamless End-to-End Service

From library construction and quality control to in vivo screening, binder recovery, and sequence analysis, Creative Biolabs provides a fully integrated workflow. Our comprehensive platform ensures consistency, efficiency, and data integrity at every stage, reducing the complexity of multi-vendor coordination.

Accelerated Timelines

With well-established phage display platforms, a high-throughput screening system, and optimized in vivo workflows, we can shorten project timelines without compromising quality. Our streamlined processes allow for rapid turnaround from concept to validated candidates, helping you advance your research or product development faster.

Proven Track Record of Success

Creative Biolabs has supported numerous global clients in identifying novel vascular targets and developing plaque-specific ligands. Our strong publication record and client satisfaction highlight our commitment to scientific excellence and reliable project execution, ensuring confidence in every collaboration.

See our full list of offerings here.

Deliverables

At the completion of an atherosclerosis targeting project, Creative Biolabs typically provides:

Comprehensive project report summarizing workflow, optimization steps, and key findings.
List of enriched peptide sequences with binding profiles.
Raw sequencing data (Sanger or NGS).
Phage clones or peptide synthesis for further testing (upon request).
Validation results from ex vivo or in vivo assays (if included in project scope).

Additional deliverables, such as peptide conjugates or animal imaging results, are available upon request. If you have any questions, please contact Creative Biolabs today to connect with our specialist team.

FAQ

Q: What animal models does Creative Biolabs use for atherosclerosis targeting?
A: We routinely work with ApoE knockout (ApoE-/-) and LDL receptor knockout (LDLR-/-) mice fed on a high-fat diet to develop robust atherosclerotic plaques.
Q: Can Creative Biolabs screen for ligands that differentiate early versus advanced plaques?
A: Yes, by adjusting circulation time, tissue collection points, and validation assays, we can help you discover ligands specific to plaque maturity stages.
Q: How are peptides validated after in vivo screening?
A: Typically, we perform ex vivo binding assays, histological co-localization studies, and optionally in vivo imaging studies to validate specificity.
Q: How long does an atherosclerosis-targeting project take?
A: Standard timelines range from 10–16 weeks, depending on project complexity and validation requirements.
Q: Can I request multiple tissue targets within the same screening campaign?
A: Absolutely. Creative Biolabs can design multiplex targeting projects upon request to maximize the output of a single screening run.

Resources

Use the resources in our library to help you understand your options and make critical decisions for your study.

VideosPodcastsInfographicFlyerCase studyArticles

Phage Display Technology

Antibody Library Screening

Phage Display Technology

Antibody Library Screening

Development of Monoclonal Antibodies

A Brief Introduction to Antibodies

Anti-idiotype Antibody Production

Phage Display Technology in Creative Biolabs

Antibody Development by Immune Phage Library

MemDX™ Therapeutic Antibody Discovery Platform

Antibody Development Case Study

Surface Display Overview

Phage Display Technology as a Powerful Platform for Antibody Drug Discovery

Basics of Antibody Phage Display Technology

Immune Antibody Phage Libraries for the Production of Antibodies to Infectious Diseases

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: